Search

Introduction and purpose Irritable bowel syndrome (IBS) is a prevalent digestive condition marked by symptoms like abdominal discomfort, bloating, and irregular bowel movements. Sodium butyrate, a short-chain fatty acid recognized for its anti-inflammatory effects and benefits to gut health, has gained attention as a potential treatment for IBS. This review seeks to assess the existing research on the effectiveness and safety of sodium butyrate in managing IBS. Material and methods This work was based on a review of the literature available on PubMed. We included studies corresponding to the keywords: sodium butyrate, irritable bowel disease, butyric acid. Results Research has shown that sodium butyrate supplementation significantly alleviated abdominal pain, bloating, and overall IBS symptoms compared to a placebo. Notable improvements were seen in both visceral pain sensitivity and gut permeability. Furthermore, combining sodium butyrate with probiotics may offer additional benefits. The treatment was generally well-tolerated, easily accessible, and cost-effective. Conclusion Sodium butyrate shows promise as a therapeutic option for managing IBS, with studies indicating its effectiveness in reducing symptoms and enhancing gut health. However, more extensive, well-structured clinical trials are required to validate these results, determine optimal dosage, and assess long-term safety and efficacy.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. It affects a large proportion of the general population leading to a negative effect on the quality of life. The pathophysiology of IBS is not fully known. There are several therapies currently used in the treatment of IBS. They vary from changing dietary habits to antibiotic therapy and must be personalized.